Advanced Biomed enters into collaboration agreement with Chi-Mei Medical

Advanced Biomed (ADVB) announced the Company has entered into a clinical research collaboration agreement with Chi-Mei Medical Center to initiate a 120-case feasibility study designed to evaluate the predictive accuracy of the Company’s A+PerfusC, a perfusion-based 3D cell culture in a compact incubator designed to replicate human physiological conditions in vitro. The feasibility study is a non-interventional clinical research project that received Institutional Review Board approval. Case collection has begun in early February 2026 at Chi-Mei Medical Center, with interim comparative data expected in May-June 2026 and full study completion targeted by year-end 2026.